Doubling up for half-life

At least five replacement therapies are marketed for hemophilia, and it is relatively easy to make recombinant Factor VIII and Factor IX, the missing clotting factors that lead to the disease. As a result, companies generally compete by tailoring dosing methods and schedules to a broader set of patient preferences.

Under a pair of deals announced last week, Wyeth is

Read the full 591 word article

How to gain access

Continue reading with a
two-week free trial.